Know Cancer

forgot password

A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma

Phase 2
1 Year
29 Years
Not Enrolling

Thank you

Trial Information

A Randomized Phase II Study of Bevacizumab (NSC 704865, BB-IND# 7921) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma



- To determine the feasibility of administering bevacizumab in combination with
vincristine, topotecan hydrochloride, and cyclophosphamide (VTC) to younger patients
with refractory or first recurrent Ewing sarcoma.

- To compare the progression-free survival of patients treated with VTC with bevacizumab
vs VTC without bevacizumab.


- To estimate the response rate to 2 cycles of VTC compared to 2 cycles of

- To evaluate biological markers as related to prognosis and specifically related to
angiogenesis by encouraging concurrent enrollment on the Ewing sarcoma banking studies
(COG-AEWS02B1 and/or COG-AEWS07B1 ) and ancillary correlative endothelial cell,
surrogate marker, and angiogenic gene studies.

OUTLINE: This is a multicenter study. Patients are stratified according to time to disease
recurrence (< 2 years vs ≥ 2 years).

- Arm I (VTCB): Patients receive bevacizumab IV over 30-90 minutes on day 1, vincristine
IV on days 1, 8, and 15, and topotecan hydrochloride IV over 30 minutes and
cyclophosphamide IV over 60 minutes on days 1-5. Treatment repeats every 21 days
(except during weeks 14, 15 [course 5], 17, 18 [course 6], 26, 27 [course 9], 29, and
30 [course 10] when no chemotherapy is given) for up to 12 courses in the absence of
disease progression or unacceptable toxicity.

- Arm II (VTC): Patients receive vincristine, topotecan hydrochloride, and
cyclophosphamide as in arm I.

After completion of study therapy, patients are followed periodically.

Inclusion Criteria


Inclusion criteria:

- Diagnosis of extracranial Ewing sarcoma or primitive neuroectodermal tumor of bone or
soft tissue meeting 1 of the following criteria:

- A first recurrence of localized disease

- A first recurrence of initially metastatic disease

- Disease refractory to initial conventional therapy

- Patients must have histological verification of the malignancy at original diagnosis

- Histological confirmation of relapse is highly recommended but not mandatory

- Patients must have RECIST-measurable disease documented by clinical, radiographic, or
histological criteria

- Patients who do not have measurable disease (e.g., bone scan-determined
metastatic disease only) remain eligible for the study and will be evaluable for
disease-free progression

Exclusion criteria:

- Radiological or clinical evidence for parenchymal brain metastases or neuroaxis


Inclusion criteria:

- Karnofsky performance status (PS) 50-100% (> 16 years of age) OR Lansky PS 50-100% (≤
16 years of age )

- Life expectancy ≥ 8 weeks

- Absolute neutrophil count ≥ 1,000/μL

- Platelet count ≥ 75,000/μL* (transfusion independent)

- Hemoglobin ≥ 8.0 g/dL* (may receive RBC transfusions)

- Direct bilirubin ≤ 1.5 times upper limit of normal (ULN) for age

- ALT ≤ 5 times ULN for age

- Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine normal for

- Urine protein:creatinine ratio ≤ 0.5 OR 24-hour urine protein < 1,000 mg

- Shortening fraction > 28% OR ejection fraction > 50%

- Hypertension must be well controlled on stable doses of medication for ≥ 2 weeks
prior to enrollment

- Negative pregnancy test

- Female patients who are lactating must agree to stop breast-feeding

- Sexually active patients of childbearing potential must agree to use effective
contraception NOTE: *Patients with tumor metastatic to bone marrow are permitted to
receive transfusions to maintain hemoglobin and platelet counts. These patients will
not be evaluable for hematologic toxicity. Patients who are refractory to platelet
infusions (i.e., unable to maintain platelet counts > 75,000/μL) and have marrow
involvement and platelet counts < 75,000/μL are not eligible.

Exclusion criteria:

- Documented, chronic nonhealing wound, ulcer, or significant traumatic injury (those
with bone fractures, including pathological fractures, or requiring surgical
intervention) within the past 28 days

- Other bone complications

- Deep venous thrombosis (including pulmonary embolism) within the past 3 months

- Recent (i.e., within 6 months) arterial thromboembolic events, including transient
ischemic attack or cerebrovascular accident

- History of myocardial infarction, severe or unstable angina, or peripheral vascular


Inclusion criteria:

- See Disease Characteristics

- Fully recovered from the acute toxic effects of all prior chemotherapy,
immunotherapy, or radiotherapy

- Recovered from any prior surgical procedure

- Prior initial therapy with topotecan hydrochloride is allowed as long as > 2 years
have elapsed since the initial diagnosis of Ewing sarcoma

- Prior therapy with cyclophosphamide or vincristine is allowed

- Minor surgical procedures (e.g., biopsies) for limited purposes of tissue retrieval

- Minor procedures include indwelling IV catheter placement and needle biopsy for
diagnostic purposes

- For minor surgeries, patients should not receive the first planned dose of
bevacizumab until the wound is healed and 7 days have elapsed

- At least 6 months since prior craniospinal radiotherapy or radiotherapy to ≥ 50% of
the pelvis

- At least 3 months since prior autologous stem cell transplantation (SCT)

- At least 6 weeks since other prior substantial bone marrow radiation

- At least 28 days since prior major surgical procedures (e.g., resection of tumor,
laparotomy, thoracotomy, or open biopsy)

- At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)

- At least 2 weeks since prior local palliative radiotherapy (e.g., small port)

- At least 1 week since prior therapy with a biologic agent or growth factor

- Patients on full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 are eligible
if both of these criteria are met:

- The patient has an in-range INR (usually between 2 and 3) on a stable dose of
oral anticoagulant or on a stable dose of low molecular weight heparin

- The patient has no active bleeding or pathological condition that carries a high
risk of bleeding (e.g., tumor involving major vessels or known varices)

Exclusion criteria:

- Prior bevacizumab

- Prior allogeneic SCT

- Radiotherapy or surgery for local control of recurrent disease concurrently with
bevacizumab (bevacizumab must be held if radiotherapy or surgery is required)

- Radiotherapy to localized painful lesions is allowed, provided ≥ 1 measurable
lesion is not irradiated

- Radiotherapy for local metastatic tumor control allowed after the first 2
courses of therapy

- Other cancer chemotherapy or immunomodulating agents

- Steroid use is allowed

Type of Study:


Study Design:

Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Feasibility of administering bevacizumab with chemotherapy

Safety Issue:


Principal Investigator

Patrick J. Leavey, MD

Investigator Role:

Study Chair

Investigator Affiliation:

University of Texas Southwestern Medical Center at Dallas


United States: Food and Drug Administration

Study ID:




Start Date:

February 2008

Completion Date:

Related Keywords:

  • Sarcoma
  • recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
  • Ewing sarcoma of bone
  • peripheral primitive neuroectodermal tumor
  • extraosseous Ewing sarcoma
  • Sarcoma, Ewing's
  • Neuroectodermal Tumors, Primitive, Peripheral
  • Sarcoma



Children's Hospital of Philadelphia Philadelphia, Pennsylvania  19104
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center Farmington, Connecticut  06360-2875
Baystate Regional Cancer Program at D'Amour Center for Cancer Care Springfield, Massachusetts  01199
Penn State Cancer Institute at Milton S. Hershey Medical Center Hershey, Pennsylvania  17033-0850
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina  27599-7570
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland  21231-2410
Cancer Research Center of Hawaii Honolulu, Hawaii  96813
Cleveland Clinic Taussig Cancer Center Cleveland, Ohio  44195
Children's Hospital of Orange County Orange, California  92668
Children's National Medical Center Washington, District of Columbia  20010-2970
Children's Mercy Hospital Kansas City, Missouri  64108
Children's Hospital and Regional Medical Center - Seattle Seattle, Washington  98105
Nemours Children's Clinic Jacksonville, Florida  32207
Driscoll Children's Hospital Corpus Christi, Texas  78466
Phoenix Children's Hospital Phoenix, Arizona  85016-7710
Southern California Permanente Medical Group Downey, California  90242
Children's Hospital Central California Madera, California  93638-8762
Kosair Children's Hospital Louisville, Kentucky  40202-3830
East Tennessee Children's Hospital Knoxville, Tennessee  37901
Blumenthal Cancer Center at Carolinas Medical Center Charlotte, North Carolina  28232-2861
Overlook Hospital Summit, New Jersey  07902-0220
Lee Cancer Care of Lee Memorial Health System Fort Myers, Florida  33901
Florida Hospital Cancer Institute at Florida Hospital Orlando Orlando, Florida  32803-1273
Sacred Heart Cancer Center at Sacred Heart Hospital Pensacola, Florida  32504
St. Joseph's Cancer Institute at St. Joseph's Hospital Tampa, Florida  33607
Kaplan Cancer Center at St. Mary's Medical Center West Palm Beach, Florida  33407
St. Vincent Indianapolis Hospital Indianapolis, Indiana  46260
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital Baltimore, Maryland  21215
Albert Einstein Cancer Center at Albert Einstein College of Medicine Bronx, New York  10461
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio  45229-3039
Rainbow Babies and Children's Hospital Cleveland, Ohio  44106-5000
Hollings Cancer Center at Medical University of South Carolina Charleston, South Carolina  29425
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas, Texas  75390
Methodist Children's Hospital of South Texas San Antonio, Texas  78229-3993
Primary Children's Medical Center Salt Lake City, Utah  84113-1100
James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York  14642
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California  94115
Alfred I. duPont Hospital for Children Wilmington, Delaware  19803
Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana  46202-5289
Lucille P. Markey Cancer Center at University of Kentucky Lexington, Kentucky  40536-0093
Tulane Cancer Center Office of Clinical Research Alexandria, Louisiana  71315-3198
Butterworth Hospital at Spectrum Health Grand Rapids, Michigan  49503-2560
Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota  55455
Children's Hospitals and Clinics of Minnesota - Minneapolis Minneapolis, Minnesota  55404
University of Mississippi Cancer Clinic Jackson, Mississippi  39216-4505
University of New Mexico Cancer Center Albuquerque, New Mexico  87131-5636
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center New York, New York  10032
Akron Children's Hospital Akron, Ohio  44308-1062
Nationwide Children's Hospital Columbus, Ohio  43205-2696
Oklahoma University Cancer Institute Oklahoma City, Oklahoma  73104
Stanford Cancer Center Stanford, California  94305-5824
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham Birmingham, Alabama  35294
Greenville Hospital Cancer Center Greenville, South Carolina  29605